BBIO — BridgeBio Pharma, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2019-06-27.
Performance
Technicals
Others in Healthcare
Measured signals that fired on BBIO
| date | signal | measured base rate |
|---|---|---|
| 2026-08-19 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-08-14 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-07-09 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
| 2026-07-06 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-06-29 | Bollinger bandwidth breaks out of its own compression structure | -0.63% over 21 days · t = -2.80 · n = 7,196 statistically distinguishable from its control group |
| 2026-06-26 | Volume shock without a price move price | -1.33% over 21 days · t = -4.53 · n = 16,432 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-19 | Kumar Neil Chief Executive Officer | Open-market sale 10b5-1 plan | 8.1K | 83.86 | 679.3K |
| 2026-08-19 | Kumar Neil Chief Executive Officer | Open-market sale 10b5-1 plan | 1.8K | 84.69 | 152.4K |
| 2026-08-19 | Kumar Neil Chief Executive Officer | Open-market sale 10b5-1 plan | 100 | 85.65 | 8.6K |
| 2026-08-18 | Kumar Neil Chief Executive Officer | Open-market sale 10b5-1 plan | 17.3K | 82.21 | 1.4M |
| 2026-08-18 | Kumar Neil Chief Executive Officer | Open-market sale 10b5-1 plan | 14.6K | 82.99 | 1.2M |
| 2026-08-18 | Kumar Neil Chief Executive Officer | Open-market sale 10b5-1 plan | 1.9K | 81.15 | 154.2K |
| 2026-08-18 | Kumar Neil Chief Executive Officer | Open-market sale 10b5-1 plan | 1.2K | 83.77 | 100.4K |
| 2026-08-16 | Kumar Neil Chief Executive Officer | Shares withheld for tax | 36.2K | 79.86 | 2.9M |
| 2026-08-16 | Trimarchi Thomas President and CFO | Shares withheld for tax | 22.8K | 79.86 | 1.8M |
| 2026-08-16 | Apuli Maricel Chief Accounting Officer | Shares withheld for tax | 4.7K | 79.86 | 376.5K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| BlackRock, Inc. | 1.1B | 14.2M |
| Kohlberg Kravis Roberts & Co. L.P. | 984.8M | 13.3M |
| JANUS HENDERSON GROUP PLC | 978.6M | 13.2M |
| VIKING GLOBAL INVESTORS LP | 879.4M | 11.8M |
| FARALLON CAPITAL MANAGEMENT LLC | 695.5M | 9.4M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 600.1M | 8.1M |
| VANGUARD CAPITAL MANAGEMENT LLC | 576.2M | 7.8M |
| Aisling Capital Management LP | 378.0M | 5.1M |
| GEODE CAPITAL MANAGEMENT, LLC | 371.9M | 4.9M |
| STATE STREET CORP | 366.4M | 4.9M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- 10 Health Care Stocks Whale Activity In Today’s Session · 2026-08-21 · benzinga
- Bridgebio Pharma, Inc. (BBIO) filed form 8-K · 2026-08-17 · SEC EDGAR
- Earnings Volatility Watch: Applied Materials and 10 Other Stocks Could See Double-Digit Moves This Week · 2026-08-09 · benzinga
Ask the AI about BBIO
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →